



**A 'ONE-STOP-SHOP' INTERVENTION INTEGRATING POINT-OF-CARE HCV RNA TESTING TO ENHANCE HEPATITIS C TESTING AND TREATMENT UPTAKE AMONG NEW RECEPTIONS TO PRISON: THE PIVOT STUDY**

Sheehan Y, Cunningham E, Cochrane A, Byrne M, Brown T, McGrath C, Lafferty L, Tedla N, Lloyd AR, and Grebely J



INHSU 2021 | 14 October 2021

# Disclosure statement

No personal disclosures.

# Importance of prisons in elimination


- Australia on track to achieve WHO 2030 targets
- Prisons key venues for HCV elimination



# Australian prison setting

- ~110 adult correctional centres
- Unique physical structure, overcrowding
- Highly transient (frequent movements), predominantly short stay
- High rates of drug-related incarceration; high rates of injecting drug use
- High chronic HCV prevalence (10-15%)
- Limited nursing capacity, competing priorities
- Reception centres (prison entrance)
- High throughput approx. 20 per week - 20 per day

# Care cascade



# Finger-stick testing for HCV RNA detection



## Xpert® HCV VL fingerstick assay

- High sensitivity & specificity (100% & 100% respectively);<sup>4</sup> comparable with traditional laboratory tests
- Quantifiable HCV RNA result in 60 mins
- Potential standalone assay (no prior Ab testing)
- Single-visit diagnosis; one step closer to single-visit test and treat
- Efficiency dependent on prevalence in setting

# Study objectives



**Primary objective:** to evaluate a 'one-stop-shop' intervention integrating point-of-care HCV RNA testing, fibroscan, clinical assessment, and fast-tracked DAA prescription, on treatment uptake among people recently incarcerated

**Primary endpoint:** treatment initiation at 12 weeks from enrolment

## Secondary objectives:

1. To compare the proportion of people tested for HCV prior to and following the intervention
2. To compare the time taken from enrolment to treatment initiation

# Participant eligibility

**Location:** reception prison on the Mid North Coast NSW

## Participant eligibility

Inclusion criteria:

- $\geq 18$  years old
- Newly incarcerated males (within previous 6 weeks);
- DAA treatment naïve.

Exclusion criteria for treatment initiation:


- HBV co-infection;
- Invalid fibroscan;
- Evidence of cirrhosis.



Mid North Coast Correctional Centre



# Methods



# 'One-stop-shop' intervention



HCV RNA PoC +  
interview survey +  
clinical assessment +  
fibroscan



Fast-tracked  
pan-  
genotypic  
DAA  
prescription



Fast-tracked  
treatment  
initiation



# Results



## Control: standard of care

Event	Number (%)
Enrolled	240
Ever injected (at risk)	116/240 (48%)
HCV Ab / RNA testing	43/240 (18%)
HCV RNA positive	19/43 (44%)
DAA treatment initiated	5/19 (26%)

90 days

## 'One-stop-shop' intervention

Event	Number (%)
Enrolled	301
Ever injected (at risk)	125/301 (42%)
HCV RNA PoC testing	298/301 (99%)
HCV RNA positive	30/298 (10%)
DAA treatment initiated	28/30 (93%)

6 days

$p < 0.001$

$p < 0.001$

$p < 0.001$

# Discussion

- Funding for a dedicated research nurse and correctional officer; dedicated clinic space
- Cost-effectiveness analysis
- Other prison-based PoC testing projects: NSW, SA, UK<sup>5</sup>
- Interest from prisons & exploring utility of PoC testing

# Conclusions



- A 'one-stop-shop' intervention integrating PoC testing enhanced testing and treatment uptake
- Markedly reduced time & increased efficiencies for treatment initiation
- Overcome key barriers to treatment scale-up in the prison sector
- Scaling up PoC testing in prisons more broadly will be good for national elimination

# Acknowledgements



## Participants and collaborators:

We would like to thank all the participants and collaborators.

**Health**Justice Health &  
Forensic Mental Health Network**Justice**

Corrective Services



## PIVOT study

- Andrew Lloyd (Kirby Institute)
- Marianne Byrne (Kirby Institute)
- Jason Grebely (Kirby Institute)
- Lise Lafferty (Kirby Institute/CSRH)
- Evan Cunningham (Kirby Institute)
- Amanda Cochrane (JHFMHN)
- Tracey Brown (JHFMHN)
- Colette McGrath (JHFMHN)
- Tom Wright (JHFMHN)

**Funders:**